SHANGHAI & BOSTON--(BUSINESS WIRE)--Backed by Hillhouse Capital (“Hillhouse”), Overland Pharmaceuticals (“Overland”) today announced its official launch with a mission to bring innovative medicines to underserved patients in Asia and around the world. The global investment firm Hillhouse is providing Overland with support to build a fully integrated biopharmaceutical company through collaborations in select disease areas. Overland brings to collaboration partners a team of highly experienced biotech leaders with a strong track record of achieving drug approvals in greater China.
Overland was co-founded by Hillhouse Venture Partners Hua Mu, MD, PhD, Interim Chief Executive Officer and Chief Medical Officer, and Ed Zhang, MBA, Chief Operating Officer and Chief Business Officer, who are veteran life sciences executives with demonstrated skill in navigating the intercontinental biopharma landscape. The company will operate in three international offices in Shanghai and Beijing, China and Boston, Massachusetts.
“Overland Pharmaceuticals is named after the teamwork required to climb and conquer the mountainous opportunities and obstacles in the healthcare industry,” said Hua Mu, Co-Founder, Interim Chief Executive Officer and Chief Medical Officer of Overland Pharmaceuticals. “Under a long-term working relationship with Hillhouse and guided by the spirit and ambition of a nimble biotech, we are excited by the promise of bringing advances in medicine to patients in Asia and around the world.”
Leveraging Hillhouse’s global network and the local biopharmaceutical ecosystem in Asia, Overland management plans to execute on its strategy to form partnerships with biotechnology companies seeking to expand the development and commercialization of their innovative therapeutic programs and cutting-edge technology platforms.
Ed Zhang, Co-Founder, Chief Operating Officer and Chief Business Officer added, “With the launch of Overland, we are creating a robust research and development engine in parallel with the significant growth and opportunity presented by Asia’s evolving biotech industry. Our focus on partnering to accelerate patient access to innovative medicines underscores our commitment to advancing breakthroughs in biomedicine such as antibody drug conjugates, cell therapy, RNAi and more. We look forward to developing and advancing our differentiated pipeline of novel therapeutics in carefully selected disease areas.”
About Overland Pharmaceuticals
Overland Pharmaceuticals is building a fully integrated biopharma company with a mission to bring innovative medicines to underserved patients in Asia and around the world. By leveraging our resources, global network, and local expertise across the biopharma ecosystem in Asia, Overland is establishing a portfolio of differentiated therapeutic candidates in a few carefully selected therapeutic areas. Through formative partnerships, Overland will move forward the development and commercialization of the most promising advances in medicine. www.overlandpharma.com
About Hillhouse Capital
Founded in 2005, Hillhouse Capital is a global firm of investment professionals and operating executives who are focused on building and investing in high quality business franchises that achieve sustainable growth. Independent proprietary research and industry expertise, in conjunction with world-class operating and management capabilities, are key to Hillhouse Capital’s investment approach. Hillhouse Capital partners with exceptional entrepreneurs and management teams to create value, often with a focus on enacting innovation and technological transformation. Hillhouse Capital invests in the healthcare, consumer, TMT, advanced manufacturing, financial and business services sectors in companies across all equity stages. Hillhouse Capital and its group members manage assets on behalf of global institutional clients.